{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T04:37:37Z","timestamp":1780547857303,"version":"3.54.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T00:00:00Z","timestamp":1690156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T00:00:00Z","timestamp":1690156800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hum Hypertens"],"DOI":"10.1038\/s41371-023-00851-9","type":"journal-article","created":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T13:02:37Z","timestamp":1690203757000},"page":"1049-1055","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Comparison of the effects of angiotensin receptor\u2013neprilysin inhibitors and thiazide diuretic\/renin\u2013angiotensin system inhibitor combination therapy in hypertensive patients: a retrospective cohort study"],"prefix":"10.1038","volume":"37","author":[{"given":"Ryunosuke","family":"Mitsuno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5173-1263","authenticated-orcid":false,"given":"Kiyotaka","family":"Uchiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashin","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rina","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norifumi","family":"Yoshimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4917-033X","authenticated-orcid":false,"given":"Shintaro","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Washida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaori","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2514-4919","authenticated-orcid":false,"given":"Hiroshi","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,24]]},"reference":[{"key":"851_CR1","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1111\/jch.13713","volume":"22","author":"T Kabutoya","year":"2020","unstructured":"Kabutoya T, Hoshide S, Kario K. Asian management of hypertension: current status, home blood pressure, and specific concerns in Japan. J Clin Hypertens (Greenwich). 2020;22:486\u201392. https:\/\/doi.org\/10.1111\/jch.13713","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"851_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/hjh.0000000000000065","volume":"32","author":"MA Weber","year":"2014","unstructured":"Weber MA, Schiffrin EL, White WB, Mann S, Lindholm LH, Kenerson JG, et al. Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension. J Hypertens. 2014;32:3\u201315. https:\/\/doi.org\/10.1097\/hjh.0000000000000065","journal-title":"J Hypertens"},{"key":"851_CR3","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJ McMurray","year":"2014","unstructured":"McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993\u20131004. https:\/\/doi.org\/10.1056\/NEJMoa1409077","journal-title":"N Engl J Med"},{"key":"851_CR4","first-page":"330","volume":"8","author":"L Fala","year":"2015","unstructured":"Fala L. Entresto (Sacubitril\/Valsartan): first-in-class angiotensin receptor neprilysin inhibitor FDA approved for patients with heart failure. Am Health Drug Benefits. 2015;8:330\u20134.","journal-title":"Am Health Drug Benefits"},{"key":"851_CR5","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1111\/jch.14120","volume":"23","author":"DS Lin","year":"2021","unstructured":"Lin DS, Wang TD, Buranakitjaroen P, Chen CH, Cheng HM, Chia YC, et al. Angiotensin receptor neprilysin inhibitor as a novel antihypertensive drug: evidence from Asia and around the globe. J Clin Hypertens (Greenwich). 2021;23:556\u201367. https:\/\/doi.org\/10.1111\/jch.14120","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"851_CR6","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/S0140-6736(09)61966-8","volume":"375","author":"LM Ruilope","year":"2010","unstructured":"Ruilope LM, Dukat A, B\u00f6hm M, Lacourci\u00e8re Y, Gong J, Lefkowitz MP. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet. 2010;375:1255\u201366. https:\/\/doi.org\/10.1016\/S0140-6736(09)61966-8","journal-title":"Lancet."},{"key":"851_CR7","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/hr.2015.1","volume":"38","author":"S Ito","year":"2015","unstructured":"Ito S, Satoh M, Tamaki Y, Gotou H, Charney A, Okino N, et al. Safety and efficacy of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Japanese patients with hypertension and renal dysfunction. Hypertens Res. 2015;38:269\u201375. https:\/\/doi.org\/10.1038\/hr.2015.1","journal-title":"Hypertens Res"},{"key":"851_CR8","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.clinthera.2013.02.021","volume":"35","author":"M Nishiwaki","year":"2013","unstructured":"Nishiwaki M, Hosoai H, Ikewaki K, Ayaori M, Yamashita T, Shige H, et al. Efficacy and effects on lipid metabolism of combination treatment with losartan + hydrochlorothiazide versus losartan + amlodipine: a 48-week prospective, multicenter, randomized, open-label trial. Clin Ther. 2013;35:461\u201373. https:\/\/doi.org\/10.1016\/j.clinthera.2013.02.021","journal-title":"Clin Ther"},{"key":"851_CR9","doi-asserted-by":"publisher","first-page":"2611","DOI":"10.2147\/DDDT.S151449","volume":"12","author":"G Derosa","year":"2018","unstructured":"Derosa G, Gaudio G, Pasini G, D\u2019Angelo A, Maffioli P. A randomized, double-blind clinical trial of canrenone vs hydrochlorothiazide in addition to angiotensin II receptor blockers in hypertensive type 2 diabetic patients. Drug Des Devel Ther. 2018;12:2611\u201316. https:\/\/doi.org\/10.2147\/DDDT.S151449","journal-title":"Drug Des Devel Ther"},{"key":"851_CR10","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/0002-9149(87)91182-9","volume":"59","author":"AV Zezulka","year":"1987","unstructured":"Zezulka AV, Gill JS, Dews I, Joy MD, Beevers DG. Comparison of enalapril and bendrofluazide for treatment of systemic hypertension. Am J Cardiol. 1987;59:630\u20133. https:\/\/doi.org\/10.1016\/0002-9149(87)91182-9","journal-title":"Am J Cardiol"},{"key":"851_CR11","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1038\/s41440-019-0284-9","volume":"42","author":"S Umemura","year":"2019","unstructured":"Umemura S, Arima H, Arima S, Asayama K, Dohi Y, Hirooka Y. et al. The Japanese society of hypertension guidelines for the management of hypertension (JSH). Hypertens Res. 2019;42:1235\u2013481. https:\/\/doi.org\/10.1038\/s41440-019-0284-9.","journal-title":"Hypertens Res"},{"key":"851_CR12","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","volume":"53","author":"S Matsuo","year":"2009","unstructured":"Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982\u201392. https:\/\/doi.org\/10.1053\/j.ajkd.2008.12.034","journal-title":"Am J Kidney Dis"},{"key":"851_CR13","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1053\/j.ajkd.2007.05.025","volume":"50","author":"B Rodriguez-Iturbe","year":"2007","unstructured":"Rodriguez-Iturbe B, Romero F, Johnson RJ. Pathophysiological mechanisms of salt-dependent hypertension. Am J Kidney Dis. 2007;50:655\u201372. https:\/\/doi.org\/10.1053\/j.ajkd.2007.05.025","journal-title":"Am J Kidney Dis"},{"key":"851_CR14","doi-asserted-by":"publisher","first-page":"252","DOI":"10.3164\/jcbn.19-61","volume":"65","author":"E Ushigome","year":"2019","unstructured":"Ushigome E, Oyabu C, Iwai K, Kitagawa N, Kitae A, Kimura T, et al. Effects of dietary salt restriction on home blood pressure in diabetic patients with excessive salt intake: a pilot study. J Clin Biochem Nutr. 2019;65:252\u20137. https:\/\/doi.org\/10.3164\/jcbn.19-61","journal-title":"J Clin Biochem Nutr"},{"key":"851_CR15","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1111\/j.1523-1755.2005.67119.x","volume":"67","author":"TA Williams","year":"2005","unstructured":"Williams TA, Mulatero P, Filigheddu F, Troffa C, Milan A, Argiolas G, et al. Role of HSD11B2 polymorphisms in essential hypertension and the diuretic response to thiazides. Kidney Int. 2005;67:631\u20137. https:\/\/doi.org\/10.1111\/j.1523-1755.2005.67119.x","journal-title":"Kidney Int"},{"key":"851_CR16","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1126\/science.7839143","volume":"267","author":"SW John","year":"1995","unstructured":"John SW, Krege JH, Oliver PM, Hagaman JR, Hodgin JB, Pang SC, et al. Genetic decreases in atrial natriuretic peptide and salt-sensitive hypertension. Science. 1995;267:679\u201381. https:\/\/doi.org\/10.1126\/science.7839143","journal-title":"Science"},{"key":"851_CR17","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s11906-010-0167-6","volume":"13","author":"H Sanada","year":"2011","unstructured":"Sanada H, Jones JE, Jose PA. Genetics of salt-sensitive hypertension. Curr Hypertens Rep. 2011;13:55\u201366. https:\/\/doi.org\/10.1007\/s11906-010-0167-6","journal-title":"Curr Hypertens Rep"},{"key":"851_CR18","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1161\/HYPERTENSIONAHA.113.02002","volume":"63","author":"K Kario","year":"2014","unstructured":"Kario K, Sun N, Chiang FT, Supasyndh O, Baek SH, Inubushi-Molessa A, et al. Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: a randomized, double-blind, placebo-controlled study. Hypertension. 2014;63:698\u2013705. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.113.02002","journal-title":"Hypertension"},{"key":"851_CR19","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.jchf.2018.02.004","volume":"6","author":"K Damman","year":"2018","unstructured":"Damman K, Gori M, Claggett B, Jhund PS, Senni M, Lefkowitz MP, et al. Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure. J.A.C.C. Heart Fail. 2018;6:489\u201398.","journal-title":"J.A.C.C. Heart Fail"},{"key":"851_CR20","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1080\/13543784.2017.1317345","volume":"26","author":"G Gervasini","year":"2017","unstructured":"Gervasini G, Robles NR. Potential beneficial effects of sacubitril-valsartan in renal disease: a new field for a new drug. Expert Opin Investig Drugs. 2017;26:651\u20139. https:\/\/doi.org\/10.1080\/13543784.2017.1317345","journal-title":"Expert Opin Investig Drugs"},{"key":"851_CR21","doi-asserted-by":"publisher","first-page":"F415","DOI":"10.1152\/ajprenal.1988.255.3.F415","volume":"255","author":"K Ohishi","year":"1988","unstructured":"Ohishi K, Hishida A, Honda N. Direct vasodilatory action of atrial natriuretic factor on canine glomerular afferent arterioles. Am J Physiol. 1988;255:F415\u2013F420. https:\/\/doi.org\/10.1152\/ajprenal.1988.255.3.F415","journal-title":"Am J Physiol"},{"key":"851_CR22","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.1093\/ndt\/gfac001","volume":"37","author":"CV Vollmer Barbosa","year":"2022","unstructured":"Vollmer Barbosa CV, Lang H, Melk A, Schmidt BMW. Renal events in patients receiving neprilysin inhibitors: a systematic review and meta-analysis. Nephrol Dial Transplant. 2022;37:2418\u201328. https:\/\/doi.org\/10.1093\/ndt\/gfac001","journal-title":"Nephrol Dial Transplant"},{"key":"851_CR23","doi-asserted-by":"publisher","first-page":"6670183","DOI":"10.1155\/2021\/6670183","volume":"2021","author":"L Ma","year":"2021","unstructured":"Ma L, Zheng K, Yan J, Cheng W. Efficacy of ARB\/HCTZ combination therapy in uncontrolled patients with hypertension compared with ARB monotherapy: a meta-analysis. Int J Hypertens. 2021;2021:6670183 https:\/\/doi.org\/10.1155\/2021\/6670183","journal-title":"Int J Hypertens"},{"key":"851_CR24","doi-asserted-by":"publisher","first-page":"17","DOI":"10.2165\/00129784-200505010-00003","volume":"5","author":"SE Kjeldsen","year":"2005","unstructured":"Kjeldsen SE, Os I, H\u00f8ieggen A, Beckey K, Gleim GW, Oparil S. Fixed-dose combinations in the management of hypertension: defining the place of angiotensin receptor antagonists and hydrochlorothiazide. Am J Cardiovasc Drugs. 2005;5:17\u201322. https:\/\/doi.org\/10.2165\/00129784-200505010-00003","journal-title":"Am J Cardiovasc Drugs"},{"key":"851_CR25","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1111\/j.1742-1241.2007.01577.x","volume":"61","author":"JM Flack","year":"2007","unstructured":"Flack JM. Maximising antihypertensive effects of angiotensin II receptor blockers with thiazide diuretic combination therapy: focus on irbesartan\/hydrochlorothiazide. Int J Clin Pract. 2007;61:2093\u2013102. https:\/\/doi.org\/10.1111\/j.1742-1241.2007.01577.x","journal-title":"Int J Clin Pract"},{"key":"851_CR26","unstructured":"Drug K Database. https:\/\/www.genome.jp\/kegg\/drug\/drug_ja.html. Accessed 12 April 2023."}],"container-title":["Journal of Human Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41371-023-00851-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41371-023-00851-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41371-023-00851-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T15:05:04Z","timestamp":1703171104000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41371-023-00851-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,24]]},"references-count":26,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["851"],"URL":"https:\/\/doi.org\/10.1038\/s41371-023-00851-9","relation":{},"ISSN":["1476-5527"],"issn-type":[{"value":"1476-5527","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,24]]},"assertion":[{"value":"28 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was reviewed and approved by the Research Ethics Committee of Keio University, School of Medicine (approval number: 20221156) and performed in accordance with the principles of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}